PARP1 and GTF2F1 |
poly(ADP-ribose) polymerase 1 |
general transcription factor IIF subunit 1 |
- POLB-Dependent Long Patch Base Excision Repair
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SUMOylation of DNA damage response and repair proteins
- HDR through MMEJ (alt-NHEJ)
- DNA Damage Recognition in GG-NER
- Formation of Incision Complex in GG-NER
- Dual Incision in GG-NER
|
- Formation of RNA Pol II elongation complex
- Formation of the Early Elongation Complex
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
- HIV Transcription Initiation
- RNA Polymerase II HIV Promoter Escape
- Transcription of the HIV genome
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Pausing and recovery of Tat-mediated HIV elongation
- Abortive elongation of HIV-1 transcript in the absence of Tat
- Tat-mediated HIV elongation arrest and recovery
- Tat-mediated elongation of the HIV-1 transcript
- HIV elongation arrest and recovery
- Pausing and recovery of HIV elongation
- Viral Messenger RNA Synthesis
- RNA Polymerase II Pre-transcription Events
- TP53 Regulates Transcription of DNA Repair Genes
- FGFR2 alternative splicing
- RNA polymerase II transcribes snRNA genes
- RNA polymerase II transcribes snRNA genes
- mRNA Capping
- mRNA Splicing - Major Pathway
- mRNA Splicing - Minor Pathway
- Processing of Capped Intron-Containing Pre-mRNA
- RNA Polymerase II Promoter Escape
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase II Transcription Initiation
- RNA Polymerase II Transcription Elongation
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- RNA Pol II CTD phosphorylation and interaction with CE
- Signaling by FGFR2 IIIa TM
- Estrogen-dependent gene expression
|
- Theophylline
- Zinc
- Carba-Nicotinamide-Adenine-Dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- Veliparib
- trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
- Olaparib
- Niraparib
- Rucaparib
|
|
|
|
PARP1 and HIPK2 |
poly(ADP-ribose) polymerase 1 |
homeodomain interacting protein kinase 2 |
- POLB-Dependent Long Patch Base Excision Repair
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SUMOylation of DNA damage response and repair proteins
- HDR through MMEJ (alt-NHEJ)
- DNA Damage Recognition in GG-NER
- Formation of Incision Complex in GG-NER
- Dual Incision in GG-NER
|
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- SUMOylation of transcription cofactors
- Physiological factors
- Regulation of TP53 Activity through Phosphorylation
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Regulation of MECP2 expression and activity
|
- Theophylline
- Zinc
- Carba-Nicotinamide-Adenine-Dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- Veliparib
- trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
- Olaparib
- Niraparib
- Rucaparib
|
|
|
|
PARP1 and IKBKG |
poly(ADP-ribose) polymerase 1 |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
- POLB-Dependent Long Patch Base Excision Repair
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SUMOylation of DNA damage response and repair proteins
- HDR through MMEJ (alt-NHEJ)
- DNA Damage Recognition in GG-NER
- Formation of Incision Complex in GG-NER
- Dual Incision in GG-NER
|
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- SUMOylation of immune response proteins
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
- Theophylline
- Zinc
- Carba-Nicotinamide-Adenine-Dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- Veliparib
- trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
- Olaparib
- Niraparib
- Rucaparib
|
|
|
- Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
- Incontinentia pigmenti
- Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
|
PARP1 and CD86 |
poly(ADP-ribose) polymerase 1 |
CD86 molecule |
- POLB-Dependent Long Patch Base Excision Repair
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SUMOylation of DNA damage response and repair proteins
- HDR through MMEJ (alt-NHEJ)
- DNA Damage Recognition in GG-NER
- Formation of Incision Complex in GG-NER
- Dual Incision in GG-NER
|
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- CTLA4 inhibitory signaling
- Interleukin-10 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Theophylline
- Zinc
- Carba-Nicotinamide-Adenine-Dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- Veliparib
- trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
- Olaparib
- Niraparib
- Rucaparib
|
- Antithymocyte immunoglobulin (rabbit)
- Abatacept
- Belatacept
|
|
|
ADRA1B and STAT1 |
adrenoceptor alpha 1B |
signal transducer and activator of transcription 1 |
- Adrenoceptors
- G alpha (q) signalling events
- G alpha (12/13) signalling events
|
- Interleukin-6 signaling
- ISG15 antiviral mechanism
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-20 family signaling
- Regulation of RUNX2 expression and activity
- Interleukin-35 Signalling
- Interleukin-9 signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- Interleukin-27 signaling
- Interleukin-21 signaling
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Growth hormone receptor signaling
|
- Amphetamine
- Midodrine
- Ziprasidone
- Cabergoline
- Dapiprazole
- Amitriptyline
- Olanzapine
- Alfuzosin
- Clozapine
- Norepinephrine
- Mirtazapine
- Phenylephrine
- Loxapine
- Promazine
- Prazosin
- Imipramine
- Chlorpromazine
- Chlorpromazine
- Nortriptyline
- Amoxapine
- Clonidine
- Doxazosin
- Labetalol
- Nicardipine
- Verapamil
- Epinephrine
- Thioridazine
- Phentolamine
- Ergotamine
- Tamsulosin
- Methoxamine
- Trimipramine
- Risperidone
- Modafinil
- Propiomazine
- Fenoldopam
- Quinidine
- Phenoxybenzamine
- Maprotiline
- Oxymetazoline
- Ergoloid mesylate
- Carvedilol
- Doxepin
- Nefazodone
- Desipramine
- Terazosin
- Pergolide
- Bromocriptine
- Quetiapine
- Aripiprazole
- Lisdexamfetamine
- Paliperidone
- Mephentermine
- Methotrimeprazine
- Dextroamphetamine
- Phendimetrazine
- Propericiazine
- Acepromazine
- Thioproperazine
- Dronedarone
- R450
- Epicept NP-1
- Sertindole
- Mianserin
- Silodosin
- Droxidopa
- Xylometazoline
- Perospirone
- Brexpiprazole
- Dosulepin
- Etoperidone
- Cirazoline
- Synephrine
- Tiapride
|
|
|
- Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
- IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency
|
ADRA1B and AP2M1 |
adrenoceptor alpha 1B |
adaptor related protein complex 2 subunit mu 1 |
- Adrenoceptors
- G alpha (q) signalling events
- G alpha (12/13) signalling events
|
- Nef mediated downregulation of CD28 cell surface expression
- Nef Mediated CD4 Down-regulation
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- Nef Mediated CD8 Down-regulation
- Gap junction degradation
- Formation of annular gap junctions
- MHC class II antigen presentation
- EPH-ephrin mediated repulsion of cells
- Recycling pathway of L1
- Recycling pathway of L1
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- VLDLR internalisation and degradation
- LDL clearance
|
- Amphetamine
- Midodrine
- Ziprasidone
- Cabergoline
- Dapiprazole
- Amitriptyline
- Olanzapine
- Alfuzosin
- Clozapine
- Norepinephrine
- Mirtazapine
- Phenylephrine
- Loxapine
- Promazine
- Prazosin
- Imipramine
- Chlorpromazine
- Chlorpromazine
- Nortriptyline
- Amoxapine
- Clonidine
- Doxazosin
- Labetalol
- Nicardipine
- Verapamil
- Epinephrine
- Thioridazine
- Phentolamine
- Ergotamine
- Tamsulosin
- Methoxamine
- Trimipramine
- Risperidone
- Modafinil
- Propiomazine
- Fenoldopam
- Quinidine
- Phenoxybenzamine
- Maprotiline
- Oxymetazoline
- Ergoloid mesylate
- Carvedilol
- Doxepin
- Nefazodone
- Desipramine
- Terazosin
- Pergolide
- Bromocriptine
- Quetiapine
- Aripiprazole
- Lisdexamfetamine
- Paliperidone
- Mephentermine
- Methotrimeprazine
- Dextroamphetamine
- Phendimetrazine
- Propericiazine
- Acepromazine
- Thioproperazine
- Dronedarone
- R450
- Epicept NP-1
- Sertindole
- Mianserin
- Silodosin
- Droxidopa
- Xylometazoline
- Perospirone
- Brexpiprazole
- Dosulepin
- Etoperidone
- Cirazoline
- Synephrine
- Tiapride
|
|
|
|
ADRB2 and SRC |
adrenoceptor beta 2 |
SRC proto-oncogene, non-receptor tyrosine kinase |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- ADORA2B mediated anti-inflammatory cytokines production
|
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- Signaling downstream of RAS mutants
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetarine
- Cabergoline
- Metoprolol
- Amitriptyline
- Olanzapine
- Atenolol
- Norepinephrine
- Mirtazapine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Trimipramine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Tulobuterol
- Levosalbutamol
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
|
|
|
ADRB2 and TSG101 |
adrenoceptor beta 2 |
tumor susceptibility 101 |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- ADORA2B mediated anti-inflammatory cytokines production
|
- Budding and maturation of HIV virion
- Membrane binding and targetting of GAG proteins
- Endosomal Sorting Complex Required For Transport (ESCRT)
- HCMV Late Events
- Late endosomal microautophagy
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetarine
- Cabergoline
- Metoprolol
- Amitriptyline
- Olanzapine
- Atenolol
- Norepinephrine
- Mirtazapine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Trimipramine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Tulobuterol
- Levosalbutamol
|
|
|
|
ADRB2 and CD81 |
adrenoceptor beta 2 |
CD81 molecule |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- ADORA2B mediated anti-inflammatory cytokines production
|
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Regulation of Complement cascade
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetarine
- Cabergoline
- Metoprolol
- Amitriptyline
- Olanzapine
- Atenolol
- Norepinephrine
- Mirtazapine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Trimipramine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Tulobuterol
- Levosalbutamol
|
|
|
|
ADRB2 and SLC52A2 |
adrenoceptor beta 2 |
solute carrier family 52 member 2 |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- ADORA2B mediated anti-inflammatory cytokines production
|
- Vitamin B2 (riboflavin) metabolism
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetarine
- Cabergoline
- Metoprolol
- Amitriptyline
- Olanzapine
- Atenolol
- Norepinephrine
- Mirtazapine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Trimipramine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Tulobuterol
- Levosalbutamol
|
- Gamma Hydroxybutyric Acid
|
|
|
ADRB2 and RAN |
adrenoceptor beta 2 |
RAN, member RAS oncogene family |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- ADORA2B mediated anti-inflammatory cytokines production
|
- Rev-mediated nuclear export of HIV RNA
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- NEP/NS2 Interacts with the Cellular Export Machinery
- Nuclear import of Rev protein
- MicroRNA (miRNA) biogenesis
- Transcriptional regulation by small RNAs
- tRNA processing in the nucleus
- Postmitotic nuclear pore complex (NPC) reformation
- Postmitotic nuclear pore complex (NPC) reformation
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetarine
- Cabergoline
- Metoprolol
- Amitriptyline
- Olanzapine
- Atenolol
- Norepinephrine
- Mirtazapine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Trimipramine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Tulobuterol
- Levosalbutamol
|
|
|
|
ADRB2 and INSR |
adrenoceptor beta 2 |
insulin receptor |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- ADORA2B mediated anti-inflammatory cytokines production
|
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- IRS activation
- Signal attenuation
- Insulin receptor signalling cascade
- Signaling by Insulin receptor
- Insulin receptor recycling
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetarine
- Cabergoline
- Metoprolol
- Amitriptyline
- Olanzapine
- Atenolol
- Norepinephrine
- Mirtazapine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Trimipramine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Tulobuterol
- Levosalbutamol
|
- Insulin Human
- Insulin Lispro
- Insulin Glargine
- Insulin Pork
- Mecasermin
- Insulin Aspart
- Insulin Detemir
- Insulin Glulisine
- Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
- NN344
- AT1391
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- Chromic chloride
- Insulin Degludec
- Brigatinib
|
|
- Rabson-Mendenhall syndrome
- Leprechaunism ; Donohue syndrome
|
ADRB2 and CD4 |
adrenoceptor beta 2 |
CD4 molecule |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- ADORA2B mediated anti-inflammatory cytokines production
|
- Alpha-defensins
- Nef Mediated CD4 Down-regulation
- Binding and entry of HIV virion
- Vpu mediated degradation of CD4
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- PD-1 signaling
- Other interleukin signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetarine
- Cabergoline
- Metoprolol
- Amitriptyline
- Olanzapine
- Atenolol
- Norepinephrine
- Mirtazapine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Trimipramine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Tulobuterol
- Levosalbutamol
|
- Antithymocyte immunoglobulin (rabbit)
|
|
|
ADRB2 and IL1B |
adrenoceptor beta 2 |
interleukin 1 beta |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- ADORA2B mediated anti-inflammatory cytokines production
|
- Interleukin-1 processing
- CLEC7A/inflammasome pathway
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-1 signaling
- Purinergic signaling in leishmaniasis infection
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetarine
- Cabergoline
- Metoprolol
- Amitriptyline
- Olanzapine
- Atenolol
- Norepinephrine
- Mirtazapine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Trimipramine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Tulobuterol
- Levosalbutamol
|
- Minocycline
- VP025
- Gallium nitrate
- Talmapimod
- Etiprednol dicloacetate
- VX-702
- VX-765
- Andrographolide
- Canakinumab
- Rilonacept
- Binimetinib
- Gevokizumab
- Dilmapimod
|
|
|
ADRB3 and SRC |
adrenoceptor beta 3 |
SRC proto-oncogene, non-receptor tyrosine kinase |
- Adrenoceptors
- G alpha (s) signalling events
- ADORA2B mediated anti-inflammatory cytokines production
|
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- Signaling downstream of RAS mutants
|
- Amphetamine
- Bethanidine
- Amitriptyline
- Olanzapine
- Norepinephrine
- Nortriptyline
- Propranolol
- Epinephrine
- Trimipramine
- Alprenolol
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Isoprenaline
- Arbutamine
- Fenoterol
- Ephedra
- Mephentermine
- Clenbuterol
- Oxprenolol
- Amibegron
- Solabegron
- Droxidopa
- Bufuralol
- Bopindolol
- Bupranolol
- Mirabegron
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
|
|
|
GRK2 and EPHA2 |
G protein-coupled receptor kinase 2 |
EPH receptor A2 |
- Calmodulin induced events
- G alpha (q) signalling events
- G alpha (s) signalling events
- Activation of SMO
- Activation of SMO
- Cargo recognition for clathrin-mediated endocytosis
|
- EPH-Ephrin signaling
- EPH-Ephrin signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- EPH-ephrin mediated repulsion of cells
|
|
- Dasatinib
- Phosphoaminophosphonic Acid-Adenylate Ester
- Regorafenib
|
|
|
GRK2 and SRC |
G protein-coupled receptor kinase 2 |
SRC proto-oncogene, non-receptor tyrosine kinase |
- Calmodulin induced events
- G alpha (q) signalling events
- G alpha (s) signalling events
- Activation of SMO
- Activation of SMO
- Cargo recognition for clathrin-mediated endocytosis
|
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- Signaling downstream of RAS mutants
|
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
|
|
|
GRK2 and CAV1 |
G protein-coupled receptor kinase 2 |
caveolin 1 |
- Calmodulin induced events
- G alpha (q) signalling events
- G alpha (s) signalling events
- Activation of SMO
- Activation of SMO
- Cargo recognition for clathrin-mediated endocytosis
|
- Triglyceride catabolism
- eNOS activation
- NOSTRIN mediated eNOS trafficking
- Basigin interactions
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- VEGFR2 mediated vascular permeability
- Extra-nuclear estrogen signaling
- FOXO-mediated transcription of cell cycle genes
|
|
|
|
- Congenital generalized lipodystrophy (CGL)
|
GRK2 and CCR5 |
G protein-coupled receptor kinase 2 |
C-C motif chemokine receptor 5 (gene/pseudogene) |
- Calmodulin induced events
- G alpha (q) signalling events
- G alpha (s) signalling events
- Activation of SMO
- Activation of SMO
- Cargo recognition for clathrin-mediated endocytosis
|
- Binding and entry of HIV virion
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
- Interleukin-10 signaling
|
|
- Maraviroc
- AMD-070
- INCB-9471
|
|
|
GRK2 and EGFR |
G protein-coupled receptor kinase 2 |
epidermal growth factor receptor |
- Calmodulin induced events
- G alpha (q) signalling events
- G alpha (s) signalling events
- Activation of SMO
- Activation of SMO
- Cargo recognition for clathrin-mediated endocytosis
|
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
- Osimertinib
- Necitumumab
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Zalutumumab
- Brigatinib
- Olmutinib
|
|
- Choriocarcinoma
- Gastric cancer
- Bladder cancer
- Oral cancer
- Glioma
- Laryngeal cancer
- Cervical cancer
- Esophageal cancer
|